<DOC>
	<DOCNO>NCT00364286</DOCNO>
	<brief_summary>The goal clinical research study learn dasatinib help control Chronic Lymphocytic Leukemia ( CLL ) . The safety drug also study . Optional Procedures : You ask additional blood sample draw . These sample use see disease respond drug .</brief_summary>
	<brief_title>Therapy Chronic Lymphocytic Leukemia With Dasatinib ( BMS-354825 )</brief_title>
	<detailed_description>Dasatinib design interfere type protein appear important survival CLL cell . If find eligible take part study , take dasatinib mouth twice day . You instruct take dasatinib morning evening . You electrocardiogram ( ECGâ€”a test electrical activity heart ) physical exam every 3 month study . Blood ( 2-3 teaspoon ) draw routine test week 1 month month rest treatment study . A bone marrow biopsy aspiration perform , need , check status disease . To collect bone marrow aspirate biopsy , area hip chest bone numb anesthetic , small amount bone marrow bone withdrawn large needle . Dasatinib give long respond . You take study disease get bad intolerable side effect occur . This investigational study . Dasatinib FDA-approved CLL , authorize use research . Up 25 patient take part multicenter study . Up 25 enrol M. D. Anderson . Optional Procedures : If agree , blood sample ( 2 tablespoon time ) collect therapy start , 3-4 hour first dose , 3 month therapy . These blood draw do routine test do . No additional needle stick need . The blood use see disease respond drug . You agree take part optional procedure order receive treatment study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Diagnosis CLL , Small lymphocytic lymphoma ( SLL ) , cell prolymphocytic leukemia ( TPLL ) . 2 . Previously treat chemotherapy monoclonal antibody . 3 . All patient Rai stage IIIIV eligible . OR Patients Rai stage 0II meet one indication treatment define NCIsponsored Working Group eligible : Massive progressive splenomegaly ; Massive lymph node , nodal cluster , progressive lymphadenopathy ; Grade 2 3 fatigue , fever &gt; /= 100.5 degree F , night sweat &gt; 2 week w/o documented infection , presence weight loss &gt; /= 10 % precede 6 month ; Progressive lymphocytosis increase lymphocyte count &gt; /= 50 % 2month period anticipate doubling time &lt; 6 month . 4 . Serum bilirubin less 2mg/dL , serum creatinine less 2mg/dL unless abnormality consider due CLL investigator . 5 . The Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; 3 . 6 . Patients must sign informed consent indicate aware investigational nature study , keep policy hospital . 7 . Sexually active woman childbearing potential must use birth control study manner risk failure minimize . Prior study enrollment woman childbearing potential must advise importance avoid pregnancy trial potential risk factor unintentional pregnancy . MUST negative pregnancy test . If pregnancy test positive patient must receive investigational product must enrol study . Men enrol study understand risk sexual partner childbearing potential practice effective birth control . 8 . Inclusion woman minority : As per NIH policy , woman member minority include protocol refer relevant population . There exclusion woman minority base study objective . 9 . New York Heart Association ( NYHA ) Class &lt; 3 10 . Patients must sign informed consent . 1 . Pregnant breastfeed woman exclude . 2 . Patients may receive concurrent chemotherapy , radiotherapy , immunotherapy . Localized radiotherapy area compromise bone marrow function apply , hematopoietic growth factor erythropoietin , GCSF , GMCSF etc . 3 . Patients must untreated uncontrolled lifethreatening infection . 4 . Uncontrolled angina within 3 month ; diagnose suspect congenital long QT syndrome ; history clinically significant ventricular arrhythmia ; prolong QTc interval ( &gt; 450 msec ) ; uncontrolled hypertension ; significant bleeding disorder unrelated cancer ; patient currently take drug generally accept risk cause Torsades de Pointes . 5 . Medications inhibit platelet function ( i.e. , aspirin , dipyridamole , epoprostenol , eptifibatide , clopidogrel , cilostazol , abciximab , ticlopidine , nonsteroidal antiinflammatory drug ) Anticoagulants ( warfarin , heparin/low molecular weight heparin [ e.g. , danaparoid , dalteparin , tinzaparin , enoxaparin ] ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>Prolymphocytic Leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>BMS-354825</keyword>
</DOC>